Benzydamine, except preparations and mixtures containing—
(a)
3 per cent or less of benzydamine when intended for application to the skin;
(b)
0,15 per cent or less of benzydamine when intended for use as a mouthrinse or for
topical application in the mouth and throat: Provided that the total dose does not exceed 36 mg of
benzydamine per day. (S1)
Bepridil.
Beta-benzalbutyramide.
Beta-galactosidase, when intended for therapeutic purposes.
Betahistine.
Betaxolol.
Bethanidine.
Bevantolol.
Bezafibrate.
Bisoprolol.
Bopindolol.
Brimonidine.
Brinzolamide.
Buflomedil.
Buformin.
Bumetanide.
Cadralazine.
Calcipotriol.
Calcium carbimide.
Calcium disodium edetate, when intended for injection.
Calcium dobesilate.
Candesartan.
Captopril.
Carazolol.
Carbachol; ophthalmic preparations thereof when intended for glaucoma. (S4)
Carbamazepine.
Carbenoxolone, except when intended for application to the oral mucosa.
Carbuterol, when contained in respirator solutions. (S2, S4)
Carprofen.
Carteolol.
Carvedilol.
Celecoxib.
Celiprolol.
Chenodeoxycholic acid.
Chlorazanil.
Chlorexolone.
Chlorothiazide and other derivatives of benzo-1,2,4-thiadiazine-7-sulphonamide-1, 1-dioxide, whether
hydrogenated or not, including hydrochlorothiazide, bendrofluazide, benzthiazide, cyclopenthiazide,
hydroflumethiazide, metchlorothiazide and polythiazide.
Chlorpropamide.
Chlorthalidone.
Chromonar.
Cilazapril.
Cimetidine, except when intended for the short-term symptomatic relief of heartburn, dyspepsia and
hyperacidity, where the maximum dose is 200 milligrams, the maximum daily dose (per 24 hours) is 800
milligrams and the maximum treatment period is 2 weeks. (S2)
Clofibrate.
Clonidine, except when intended for the treatment of migraine. (S2)
Clopidogrel.
Colchicine, except in cases of emergency. (S2)
Colestipol.
Copper salts, when intended for injection.
Corticosteroids (natural or synthetic), when contained in preparations intended for inhalation, except—
(a)
beclomethasone dipropionate, when intended for nasal administration, other than by
aerosol, indicated for the treatment of the symptoms of seasonal allergic rhinitis (hay fever) in adults and
children over 12, where the maximum dose per nostril is 100 micrograms, the maximum daily dose per
nostril is 200 micrograms and the pack size is limited to 200 doses; and
(b)
flunisolide, when intended for nasal administration, other than by aerosol, in a strength
not exceeding 0,025 per cent (w/v), indicated for treatment of the symptoms of seasonal allergic rhinitis
(hay fever) in adults and children over 12, where in the case of adults and children over the age of 16
years, the maximum dose per nostril is 50 micrograms and the maximum daily dose per nostril is 100
micrograms and in the case of children 12 to 16 years, the maximum dose per nostril is 25 micrograms
and the maximum daily dose per nostril is 75 micrograms and the pack size is limited to 240 doses; and